CA981678A - (2-imidazolin-2-ylamino) substituted - quinoxalines and-quinazolines as antihypertensive agents - Google Patents
(2-imidazolin-2-ylamino) substituted - quinoxalines and-quinazolines as antihypertensive agentsInfo
- Publication number
- CA981678A CA981678A CA164,361A CA164361A CA981678A CA 981678 A CA981678 A CA 981678A CA 164361 A CA164361 A CA 164361A CA 981678 A CA981678 A CA 981678A
- Authority
- CA
- Canada
- Prior art keywords
- quinoxalines
- quinazolines
- imidazolin
- ylamino
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919672A GB1381979A (en) | 1972-02-29 | 1972-02-29 | Amino derivatives of quinoline quinoxaline and quinazoline |
| GB5162972 | 1972-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA981678A true CA981678A (en) | 1976-01-13 |
Family
ID=26242776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA164,361A Expired CA981678A (en) | 1972-02-29 | 1973-02-22 | (2-imidazolin-2-ylamino) substituted - quinoxalines and-quinazolines as antihypertensive agents |
Country Status (16)
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1463520A (en) * | 1974-09-06 | 1977-02-02 | Pfizer Ltd | Process for the production of imidazolines |
| JPS5373571A (en) * | 1976-12-10 | 1978-06-30 | Otsuka Pharmaceut Co Ltd | Carbostyril derivatives |
| US4188393A (en) | 1977-04-22 | 1980-02-12 | Sandoz Ltd. | Treating spastic conditions or relaxing muscles |
| US4145421A (en) | 1977-04-22 | 1979-03-20 | Sandoz Ltd. | Treating spastic conditions |
| FR2449087A2 (fr) * | 1979-02-16 | 1980-09-12 | Rhone Poulenc Ind | Nouveaux derives de l'isoquinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US4486432A (en) * | 1982-09-30 | 1984-12-04 | Eli Lilly And Company | Quinoxalinedione leukotriene release inhibitors |
| FR2541680B1 (fr) * | 1983-02-24 | 1985-06-14 | Rhone Poulenc Sante | Nouveaux derives de l'amino-5 dithiole-1,2 one-3, leur preparation et les compositions medicinales qui les contiennent |
| JPS6118950U (ja) * | 1984-07-10 | 1986-02-03 | 財団法人鉄道総合技術研究所 | トロリ線の給油装置 |
| JPS63296814A (ja) * | 1987-05-29 | 1988-12-02 | Ishigaki Kiko Kk | 集塵装置における濾材の目詰り除去装置 |
| GB8827820D0 (en) * | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
| US5281591A (en) * | 1989-05-22 | 1994-01-25 | Allergan, Inc. | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure |
| US5180721A (en) * | 1989-05-22 | 1993-01-19 | Allergan, Inc. | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure |
| US5326763A (en) * | 1989-10-12 | 1994-07-05 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| US5112822A (en) * | 1989-10-12 | 1992-05-12 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
| US5077292A (en) * | 1989-10-12 | 1991-12-31 | Allergan, Inc. | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
| US5204347A (en) * | 1989-10-12 | 1993-04-20 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines |
| US5198442A (en) * | 1989-10-12 | 1993-03-30 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
| US5231096A (en) * | 1989-10-12 | 1993-07-27 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| US5021416A (en) * | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
| US5215991A (en) * | 1990-01-26 | 1993-06-01 | Allergan, Inc. | Combination of selective alpha-adrenergic agonists and Na+ /H+ ex |
| US5237072A (en) * | 1990-02-06 | 1993-08-17 | Allergan, Inc. | Method for producing amino-2-imidazoline derivatives |
| US5130441A (en) * | 1990-02-06 | 1992-07-14 | Allergan, Inc. | Method for producing amino-2-imidazoline derivatives |
| US5252595A (en) * | 1990-02-28 | 1993-10-12 | Allergan, Inc. | Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines |
| US5091528A (en) * | 1990-09-12 | 1992-02-25 | Allergan, Inc. | 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents |
| US6323204B1 (en) * | 1993-10-13 | 2001-11-27 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| DE69431880T2 (de) * | 1993-10-13 | 2003-09-18 | Allergan Inc | Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten |
| US5580892A (en) * | 1993-10-22 | 1996-12-03 | Allergan | Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents |
| US5578607A (en) * | 1993-12-17 | 1996-11-26 | The Procter & Gamble Company | 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
| US5576437A (en) * | 1993-12-17 | 1996-11-19 | The Procter & Gamble Company | 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists |
| CN1137755A (zh) * | 1993-12-17 | 1996-12-11 | 普罗克特和甘保尔公司 | 用作α-2肾上腺素能受体兴奋剂的6-(2-咪唑啉基氨基)喹喔啉化合物 |
| HU217841B (hu) * | 1993-12-17 | 2000-04-28 | The Procter & Gamble Co. | 6-[(2-Imidazolidinilidén)-amino]-kinolin-származékok és ezeket tartalmazó gyógyszerkészítmények |
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| EP0693055B1 (en) * | 1994-02-08 | 1997-05-21 | Alcon Laboratories, Inc. | Novel process for preparation of clonidine derivatives |
| CA2196792A1 (en) | 1994-08-04 | 1996-02-15 | Yoon T. Jeon | Novel benzimidazole derivatives |
| US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
| US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| US5916900A (en) * | 1995-06-29 | 1999-06-29 | The Procter & Gamble Company | 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
| DE69730516T2 (de) * | 1996-11-25 | 2005-09-01 | The Procter & Gamble Company, Cincinnati | 2-imidazolinylaminoindol verbindungen als alpha-2 adrenoceptor agonisten |
| AU5433898A (en) * | 1996-11-25 | 1998-06-22 | Procter & Gamble Company, The | 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists |
| KR20000069131A (ko) | 1996-11-25 | 2000-11-25 | 데이비드 엠 모이어 | 알파-2 아드레날린수용체 아고니스트로서 유용한 구아니디닐 헤테로사이클 화합물 |
| TR199901486T2 (xx) * | 1996-11-25 | 1999-10-21 | The Procter & Gamble Company | Alfa-2 adrenosept�r agonistleri olarak yararl� 2-imidazolinilamino-benzoksazol bile�ikleri. |
| US6306877B1 (en) | 1999-08-09 | 2001-10-23 | The Procter & Gamble Co. | Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists |
| US6172095B1 (en) | 1996-11-25 | 2001-01-09 | The Procter & Gamble Company | Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists |
| US6495583B1 (en) | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
| EP1037887B1 (en) | 1997-11-24 | 2004-07-14 | The Procter & Gamble Company | 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability |
| US6242442B1 (en) | 1998-12-17 | 2001-06-05 | Alcon Laboratories, Inc. | Brinzolamide and brimonidine for treating ocular conditions |
| PL360707A1 (en) | 2000-07-14 | 2004-09-20 | Allergan Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US20040214829A1 (en) * | 2000-07-14 | 2004-10-28 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US8858961B2 (en) * | 2000-07-14 | 2014-10-14 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US20050026924A1 (en) * | 2000-07-14 | 2005-02-03 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| KR20030023700A (ko) | 2000-07-14 | 2003-03-19 | 알러간, 인코포레이티드 | 치료활성 성분을 함유하고 용해도가 증강된 조성물 |
| DE10161767A1 (de) * | 2001-12-15 | 2003-06-26 | Merck Patent Gmbh | 2-Guanidino-4-heterocyclyl-chinazoline |
| US7642258B2 (en) * | 2002-04-19 | 2010-01-05 | Allergan, Inc. | Combination of brimonidine and timolol for topical ophthalmic use |
| US7030149B2 (en) * | 2002-04-19 | 2006-04-18 | Allergan, Inc. | Combination of brimonidine timolol for topical ophthalmic use |
| DE60318081T2 (de) * | 2002-10-08 | 2008-11-06 | Allergan, Inc., Irvine | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson |
| RU2330649C2 (ru) * | 2002-10-08 | 2008-08-10 | Аллерган, Инк. | Агонисты альфа-2в или 2в/2с адренорецепторов для лечения нейродегенеративных заболеваний |
| US20040191332A1 (en) * | 2003-03-27 | 2004-09-30 | Allergan, Inc. | Preserved ophthalmic compositions |
| US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| CA2534484A1 (en) | 2003-08-07 | 2005-02-17 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
| PL1660090T3 (pl) * | 2003-08-14 | 2013-04-30 | Array Biopharma Inc | Analogi chinazoliny jako inhibitory kinaz tyrozynowych receptora |
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| US20070042951A1 (en) * | 2003-10-08 | 2007-02-22 | Allergan, Inc. | Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides |
| EP2481412B1 (en) | 2004-05-25 | 2017-09-27 | Galderma Pharma S.A. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
| US7534795B2 (en) * | 2005-10-25 | 2009-05-19 | Allergan, Inc. | Compounds and their use related to compositions for treating disease |
| TWI435729B (zh) | 2005-11-09 | 2014-05-01 | Combinatorx Inc | 治療病症之方法，組合物及套組 |
| JP5134548B2 (ja) | 2005-11-15 | 2013-01-30 | アレイ バイオファーマ、インコーポレイテッド | 過剰増殖性疾患の処置のためのＥｒｂＢＩ型受容体チロシンキナーゼ阻害剤としてのＮ４−フェニルキナゾリン−４−アミン誘導体および関連化合物 |
| WO2008074068A1 (en) * | 2006-12-20 | 2008-06-26 | Prana Biotechnology Limited | Substituted quinoline derivatives as antiamyloidogeneic agents |
| US20080293728A1 (en) * | 2007-05-18 | 2008-11-27 | Mcintire Gregory L | Complexes Comprising alpha2-Adrenergic Receptor Agonists and Compositions |
| US7842714B2 (en) | 2008-03-03 | 2010-11-30 | Allergan, Inc. | Ketorolac tromethamine compositions for treating ocular pain |
| US9192571B2 (en) * | 2008-03-03 | 2015-11-24 | Allergan, Inc. | Ketorolac tromethamine compositions for treating or preventing ocular pain |
| EP2486009B1 (en) | 2009-10-06 | 2019-08-21 | Allergan, Inc. | 2h-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators |
| EP2329849B1 (en) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
| US8394800B2 (en) | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| US9522153B2 (en) | 2009-12-22 | 2016-12-20 | Allergan, Inc. | Compositions and methods for lowering intraocular pressure |
| KR20150055082A (ko) | 2010-03-26 | 2015-05-20 | 갈데르마 리써어치 앤드 디벨로프먼트 | 홍반의 유효하고 안전한 치료를 위한 개선된 방법 및 조성물 |
| MX2012010823A (es) | 2010-03-26 | 2012-10-10 | Galderma Res & Dev | Metodos y composiciones mejoradas para tratamiento seguro y efectivo de telangiectasia. |
| CA2796041A1 (en) | 2010-04-07 | 2011-10-13 | Allergan, Inc. | Combinations of preservative compositions for ophthalmic formulations |
| US20110251285A1 (en) | 2010-04-07 | 2011-10-13 | Allergan, Inc. | Combinations of preservatives for ophthalmic compositions |
| TR201818754T4 (tr) | 2010-07-29 | 2019-01-21 | Allergan Inc | Koruyucu içermeyen Brimonidin Ve Timolol Çözeltileri |
| US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
| KR101506102B1 (ko) | 2010-10-21 | 2015-03-25 | 갈데르마 소시에떼아노님 | 브리모니딘 겔 조성물 및 사용 방법 |
| CN103827107A (zh) | 2011-07-25 | 2014-05-28 | 阿勒根公司 | 作为α2肾上腺素能受体的调节剂的N-(咪唑烷-2-亚基)喹啉衍生物 |
| GR1009419B (el) | 2017-11-07 | 2018-12-14 | Φαρματεν Αβεε | Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3560501A (en) * | 1966-09-15 | 1971-02-02 | Ciba Geigy Corp | Process for making dihydroquinazolines |
| US3594380A (en) * | 1969-02-18 | 1971-07-20 | American Home Prod | Isoquinolin-1(2h)-ones |
| BE766039A (fr) * | 1971-04-21 | 1971-09-16 | Labofina Sa | Nouveaux polymeres contenant des unites de pyrazole et procede de preparation de ces polymeres. |
-
0
- BE BE795970D patent/BE795970A/xx not_active IP Right Cessation
-
1972
- 1972-02-29 GB GB919672A patent/GB1381979A/en not_active Expired
-
1973
- 1973-02-08 AU AU51985/73A patent/AU471598B2/en not_active Expired
- 1973-02-13 SE SE7302024A patent/SE417204B/xx unknown
- 1973-02-14 IE IE236/73A patent/IE37519B1/xx unknown
- 1973-02-14 FI FI436/73A patent/FI63757C/fi active
- 1973-02-14 US US332485A patent/US3890319A/en not_active Expired - Lifetime
- 1973-02-15 MX MX129473U patent/MX3042E/es unknown
- 1973-02-20 ES ES411804A patent/ES411804A1/es not_active Expired
- 1973-02-21 JP JP48020280A patent/JPS5754516B2/ja not_active Expired
- 1973-02-22 CA CA164,361A patent/CA981678A/en not_active Expired
- 1973-02-23 DE DE19732309160 patent/DE2309160A1/de active Pending
- 1973-02-23 AR AR246774A patent/AR213705A1/es active
- 1973-02-27 ES ES412102A patent/ES412102A1/es not_active Expired
- 1973-02-28 CH CH149075A patent/CH577500A5/xx not_active IP Right Cessation
- 1973-02-28 NL NL7302799.A patent/NL159102B/xx not_active IP Right Cessation
- 1973-02-28 CH CH293873A patent/CH576975A5/xx not_active IP Right Cessation
- 1973-02-28 FR FR7307157A patent/FR2181776B1/fr not_active Expired
-
1980
- 1980-07-11 JP JP9493480A patent/JPS5625176A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| ES411804A1 (es) | 1976-05-01 |
| AU5198573A (en) | 1974-08-08 |
| MX3042E (es) | 1980-03-04 |
| NL159102B (nl) | 1979-01-15 |
| IE37519B1 (en) | 1977-08-17 |
| GB1381979A (en) | 1975-01-29 |
| JPS5625176A (en) | 1981-03-10 |
| CH577500A5 (US06653308-20031125-C00199.png) | 1976-07-15 |
| FR2181776A1 (US06653308-20031125-C00199.png) | 1973-12-07 |
| FI63757C (fi) | 1983-08-10 |
| AR213705A1 (es) | 1979-03-15 |
| CH576975A5 (US06653308-20031125-C00199.png) | 1976-06-30 |
| FR2181776B1 (US06653308-20031125-C00199.png) | 1976-08-13 |
| JPS5754516B2 (US06653308-20031125-C00199.png) | 1982-11-18 |
| NL7302799A (US06653308-20031125-C00199.png) | 1973-08-31 |
| DE2309160A1 (de) | 1973-09-27 |
| SE417204B (sv) | 1981-03-02 |
| ES412102A1 (es) | 1976-05-16 |
| JPS5745439B2 (US06653308-20031125-C00199.png) | 1982-09-28 |
| JPS4897878A (US06653308-20031125-C00199.png) | 1973-12-13 |
| IE37519L (en) | 1973-08-29 |
| FI63757B (fi) | 1983-04-29 |
| AU471598B2 (en) | 1976-04-29 |
| BE795970A (fr) | 1973-08-27 |
| US3890319A (en) | 1975-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA981678A (en) | (2-imidazolin-2-ylamino) substituted - quinoxalines and-quinazolines as antihypertensive agents | |
| CA984843A (en) | Heterocyclic compounds | |
| AU467511B2 (en) | Dilution agent | |
| CA1014446A (en) | Perfluoralkylphosphorus compounds as foam-dampening agents | |
| CA1000721A (en) | DERIVATIVES OF .alpha.-GLUTAMYL-4-NITROANILIDE | |
| CA978946A (en) | .alpha.-ARYL-4-SUBSTITUTED PIPERIDINOALKANOL DERIVATIVES | |
| AU464534B2 (en) | Benzimidazoles | |
| CA980769A (en) | 1,2,3-triazole derivatives | |
| CA984838A (en) | N,n'-diphenyl-n-(n"-alkylcarbamoyl) formamidine derivatives | |
| AU470054B2 (en) | Sawblade | |
| CA990285A (en) | 1,2-dihydroquinobenzoxa(or thia)zepine derivatives | |
| CA1011340A (en) | 1-aryl-5-substituted tetrazoles | |
| CA1018458A (en) | Antihypertensive hydrazinopyridazine-containing mixtures | |
| ZA731406B (en) | New antihypertensive agents | |
| AU5707273A (en) | Novel benzimidazoles | |
| CA981666A (en) | 5,11-dihydrodibenzoxa(or thia)zepine derivatives | |
| CA924719A (en) | Heterocyclic compounds | |
| AU443984B2 (en) | Amidoxime o-carbamates as antihypertensive agents | |
| CA908051A (en) | Benzimidazoles useful as antifungals | |
| AU5738773A (en) | New benzimidazoles | |
| AU6592669A (en) | Amidoxime o-carbamates as antihypertensive agents | |
| CA902081A (en) | Substituted benzimidazoles | |
| CA816133A (en) | Amino-alkoxy-2-naphthyl derivatives as anti-cholesteremic agents | |
| CA914336A (en) | Block copolymer - polypropylene compositions | |
| CA897854A (en) | N-alkyl pyrrolidone-plasticized copolylactam compositions |